These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20967855)

  • 1. A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis.
    Manetti M; Allanore Y; Revillod L; Fatini C; Guiducci S; Cuomo G; Bonino C; Riccieri V; Bazzichi L; Liakouli V; Cipriani P; Giacomelli R; Abbate R; Bombardieri S; Valesini G; Montecucco C; Valentini G; Ibba-Manneschi L; Matucci-Cerinic M
    Arthritis Rheum; 2011 Jan; 63(1):247-56. PubMed ID: 20967855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?
    Manetti M; Rosa I; Milia AF; Guiducci S; Carmeliet P; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2014 Sep; 73(9):1700-9. PubMed ID: 23852693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population.
    Almasi S; Erfani N; Mojtahedi Z; Rajaee A; Ghaderi A
    Genes Immun; 2006 Jul; 7(5):401-6. PubMed ID: 16775619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population.
    Ito I; Kawaguchi Y; Kawasaki A; Hasegawa M; Ohashi J; Hikami K; Kawamoto M; Fujimoto M; Takehara K; Sato S; Hara M; Tsuchiya N
    Arthritis Rheum; 2009 Jun; 60(6):1845-50. PubMed ID: 19479858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis.
    Dieudé P; Guedj M; Wipff J; Ruiz B; Hachulla E; Diot E; Granel B; Sibilia J; Tiev K; Mouthon L; Cracowski JL; Carpentier PH; Amoura Z; Fajardy I; Avouac J; Meyer O; Kahan A; Boileau C; Allanore Y
    Arthritis Rheum; 2009 Aug; 60(8):2472-9. PubMed ID: 19644887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis.
    D'Alessio S; Fibbi G; Cinelli M; Guiducci S; Del Rosso A; Margheri F; Serratì S; Pucci M; Kahaleh B; Fan P; Annunziato F; Cosmi L; Liotta F; Matucci-Cerinic M; Del Rosso M
    Arthritis Rheum; 2004 Oct; 50(10):3275-85. PubMed ID: 15476218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis.
    Liakouli V; Manetti M; Pacini A; Tolusso B; Fatini C; Toscano A; Cipriani P; Guiducci S; Bazzichi L; Codullo V; Ruocco L; Dell'orso L; Carubbi F; Marrelli A; Abbate R; Bombardieri S; Ferraccioli G; Montecucco C; Valentini G; Matucci-Cerinic M; Ibba-Manneschi L; Giacomelli R
    Ann Rheum Dis; 2009 Apr; 68(4):584-90. PubMed ID: 18445624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between promoter region of the uPAR (rs344781) gene polymorphism in genetic susceptibility to migraine without aura in three Iranian hospitals.
    Zandifar A; Soleimani S; Iraji N; Haghdoost F; Tajaddini M; Javanmard SH
    Clin Neurol Neurosurg; 2014 May; 120():45-8. PubMed ID: 24731575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor.
    Serratì S; Cinelli M; Margheri F; Guiducci S; Del Rosso A; Pucci M; Fibbi G; Bazzichi L; Bombardieri S; Matucci-Cerinic M; Del Rosso M
    J Pathol; 2006 Oct; 210(2):240-8. PubMed ID: 16917801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population.
    Manetti M; Ibba-Manneschi L; Fatini C; Guiducci S; Cuomo G; Bonino C; Bazzichi L; Liakouli V; Giacomelli R; Abbate R; Bombardieri S; Montecucco C; Valentini G; Matucci-Cerinic M
    J Rheumatol; 2010 Sep; 37(9):1852-7. PubMed ID: 20595276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in COL15 gene are not associated with systemic sclerosis.
    Pushpakom SP; Herrick AL; Kumar S; Worthington J
    J Rheumatol; 2008 Feb; 35(2):251-3. PubMed ID: 18203317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype.
    Rueda B; Broen J; Torres O; Simeon C; Ortego-Centeno N; Schrijvenaars MM; Vonk MC; Fonollosa V; van den Hoogen FH; Coenen MJ; Sanchez-Román J; Aguirre-Zamorano MA; García-Portales R; Pros A; Camps MT; Gonzalez-Gay MA; Martin J; Radstake TR
    Ann Rheum Dis; 2009 Feb; 68(2):253-6. PubMed ID: 18713787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allograft inflammatory factor-1 and tumor necrosis factor single nucleotide polymorphisms in systemic sclerosis.
    Otieno FG; Lopez AM; Jimenez SA; Gentiletti J; Artlett CM
    Tissue Antigens; 2007 Jun; 69(6):583-91. PubMed ID: 17498268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis.
    Carulli MT; Spagnolo P; Fonseca C; Welsh KI; duBois RM; Black CM; Denton CP
    J Rheumatol; 2008 May; 35(5):839-44. PubMed ID: 18381789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort.
    Bossini-Castillo L; Broen JC; Simeon CP; Beretta L; Vonk MC; Ortego-Centeno N; Espinosa G; Carreira P; Camps MT; Navarrete N; González-Escribano MF; Vicente-Rabaneda E; Rodríguez L; Tolosa C; Román-Ivorra JA; Gómez-Gracia I; García-Hernández FJ; Castellví I; Gallego M; Fernández-Nebro A; García-Portales R; Egurbide MV; Fonollosa V; de la Peña PG; Pros A; González-Gay MA; Hesselstrand R; Riemekasten G; Witte T; Coenen MJ; Koeleman BP; Houssiau F; Smith V; de Keyser F; Westhovens R; De Langhe E; Voskuyl AE; Schuerwegh AJ; Chee MM; Madhok R; Shiels P; Fonseca C; Denton C; Claes K; Padykov L; Nordin A; Palm O; Lie BA; Airó P; Scorza R; van Laar JM; Hunzelmann N; Kreuter A; Herrick A; Worthington J; Radstake TR; Martín J; Rueda B
    Ann Rheum Dis; 2011 Apr; 70(4):638-41. PubMed ID: 21187296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.
    Tsuchiya N; Kuroki K; Fujimoto M; Murakami Y; Tedder TF; Tokunaga K; Takehara K; Sato S
    Arthritis Rheum; 2004 Dec; 50(12):4002-7. PubMed ID: 15593213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of putative functional variants in the PLAU gene and the PLAUR gene with myocardial infarction.
    Xu J; Li W; Bao X; Ding H; Chen J; Zhang W; Sun K; Wang J; Wang X; Wang H; Yu H; Song W; Ma W; Zhang L; Wang C; Wang D; Hui R
    Clin Sci (Lond); 2010 Jul; 119(8):353-9. PubMed ID: 20518747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis.
    Legány N; Toldi G; Distler JH; Beyer C; Szalay B; Kovács L; Vásárhelyi B; Balog A
    Clin Chem Lab Med; 2015 Oct; 53(11):1799-805. PubMed ID: 25894644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype-haplotype correlation of IRF5 in systemic sclerosis: role of 2 haplotypes in disease severity.
    Dieude P; Dawidowicz K; Guedj M; Legrain Y; Wipff J; Hachulla E; Diot E; Sibilia J; Mouthon L; Cabane J; Amoura Z; Crakowski JL; Carpentier P; Avouac J; Meyer O; Kahan A; Boileau C; Allanore Y
    J Rheumatol; 2010 May; 37(5):987-92. PubMed ID: 20231204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.